Scientific deep-dive

Retatrutide Before and After: What TRIUMPH-1 Actually Showed

TRIUMPH-1 (n=2,339; NEJM 2026) reported -25.0% mean weight loss at 80 weeks on retatrutide 12 mg (intention-to-treat; Lilly's press release cited -28.3% on-treatment). Honest framing of transformation magnitude, dose-response, and real-world expectations.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
12 min read·13 citations

Patients searching “retatrutide before and after” almost always want two things: photos of someone who took the drug, and a sense of what kind of transformation is realistic. We don't post patient photos or stock transformation imagery because those don't generalize and they aren't evidence. What does generalize, with appropriate caveats, is the magnitude reported in the pivotal trial. TRIUMPH-1 (NCT05929066, n=2,339) was presented at the 86th American Diabetes Association Scientific Sessions in May 2026 [1][2][8] and published in the New England Journal of Medicine in September 2026[13]. On the 12 mg dose at 80 weeks, mean total body-weight reduction in the published intention-to-treat (treatment-regimen) analysis was -25.0%, versus -3.9% on placebo[13]. Lilly's May 2026 press release headlined a larger -28.3% (about 70.3 lbs), which is the efficacy-estimand figure (participants who stayed on treatment) [1]. Per the same press release, the BMI-35-or-higher extension cohort reached -30.3% (about 85.0 lbs lost) at 104 weeks on the efficacy estimand. That is the largest mean weight loss any pharmacological obesity therapy has ever produced in a Phase 3 trial — and it approaches the magnitude historically associated with bariatric surgery. Below: the dose-response, the responder rates, side-by-side comparisons to Wegovy / Zepbound / Foundayo, and honest framing for what to expect in real-world (non-trial) use.

The honest short answer

Retatrutide 12 mg at 80 weeks produced -25.0% mean total body weight reduction in TRIUMPH-1 on the published intention-to-treat analysis, versus -3.9% on placebo[13]. That was the first pivotal Phase 3 readout in adults with obesity. Lilly's press release reported -28.3% for the same dose on the efficacy estimand, and -30.3% TBWL (-85.0 lbs) at 104 weeks in the BMI 35+ extension cohort, also on the efficacy estimand [1]. To put this in plain language: a 250 lb patient who lost the published trial mean would weigh roughly 188 lbs at 80 weeks on the 12 mg dose, or about 174 lbs at the press-release extension-cohort figure. The 4 mg starter dose produced -17.6% TBWL[13], itself larger than what Wegovy 2.4 mg produced at 68 weeks in STEP-1[6]. This is the largest pharmacological obesity result on record and it changes the framing of what a “before and after” can mean.

What TRIUMPH-1 actually showed

TRIUMPH-1 (NCT05929066) randomized 2,339 adults with obesity (or overweight plus weight-related comorbidity, no type 2 diabetes) to retatrutide 4 mg, 9 mg, 12 mg, or placebo, all once weekly subcutaneously, with the primary endpoint at 80 weeks [1][2]. The full results were published in the New England Journal of Medicine in September 2026[13]. A pre-specified extension out to 104 weeks enrolled the subset of patients with baseline BMI 35 or higher. The TRIUMPH master design (including TRIUMPH-1, -2, -3 and -4) was published by Giblin et al. in Diabetes, Obesity and Metabolism in 2026 [3]. The table below puts the published intention-to-treat (treatment-regimen) results[13] next to the efficacy-estimand figures Lilly headlined in its May 2026 press release [1][8]. The efficacy estimand estimates the effect had everyone stayed on treatment, so it always runs larger:

ArmMean TBWL (NEJM, intention-to-treat)Mean TBWL (Lilly press release, efficacy estimand)Endpoint
Retatrutide 12 mg-25.0%-28.3% (-70.3 lbs)80 weeks
Retatrutide 9 mg-23.7%-25.9% (-64.4 lbs)80 weeks
Retatrutide 4 mg-17.6%-19.0% (-47.2 lbs)80 weeks
Placebo-3.9%-2.2% (-5.5 lbs)80 weeks
Retatrutide 12 mg (extension, BMI 35+)Not reported in the NEJM abstract-30.3% (-85.0 lbs)104 weeks

The placebo arm lost 3.9% in the published analysis — consistent with the lifestyle intervention common to all GLP-1 pivotal trials (modest caloric reduction plus increased physical activity counseling). That baseline lets us isolate the drug-attributable effect at each dose: about -13.7 percentage points at 4 mg, -19.8 at 9 mg, and -21.0 at 12 mg[13].

Dose-response: 4 mg / 9 mg / 12 mg transformation magnitudes

The dose-response in TRIUMPH-1 is monotonic but compressed at the top — the same shape we saw in the SURMOUNT-1 tirzepatide trial [5] and the retatrutide Phase 2 trial. The biggest step is from 4 mg to 9 mg (about 6 additional percentage points), with diminishing returns between 9 and 12 mg (about 1.3 points). Figures below are the published intention-to-treat results[13]:

  • 4 mg starter dose: -17.6% mean TBWL at 80 weeks (-19.0% on Lilly's press-release efficacy estimand). By itself this is larger than the highest dose of Wegovy in STEP-1 (-14.9% at 68 weeks)[6] and not far below Zepbound 15 mg in SURMOUNT-1 (-20.9% at 72 weeks)[5].
  • 9 mg middle dose: -23.7% TBWL at 80 weeks (-25.9% on the press-release efficacy estimand). This is the dose most patients are expected to tolerate, and it already exceeds every approved GLP-1 single-agent and dual-agonist by a meaningful margin.
  • 12 mg top dose: -25.0% TBWL at 80 weeks (-28.3% on the press-release efficacy estimand); -30.3% in the 104-week BMI 35+ extension per Lilly's press release. The 12 mg dose is what generates the “before and after” transformations that approach bariatric-surgery magnitudes, but it also carries the highest GI adverse event rate; gastrointestinal events were the most common adverse events in the NEJM publication[13].

What ≥30% body-weight loss actually means clinically

Lilly's TRIUMPH-1 press release reported 45.3% of patients on 12 mg hit at least 30% body-weight reduction on the efficacy estimand [1]. That threshold matters because it puts retatrutide responders in the same effect-size neighborhood as bariatric surgery. In the STAMPEDE 5-year RCT (Schauer 2017 NEJM) of patients with type 2 diabetes and a mean baseline BMI of about 37, Roux-en-Y gastric bypass produced -23% mean body-weight reduction and sleeve gastrectomy produced -19% at 5 years [10]. The 10-year SLEEVEPASS RCT in patients with higher baseline BMI converts to roughly 22-24% TBWL for bypass and sleeve. Both surgeries are irreversible and carry surgical morbidity plus a permanent need for vitamin and protein supplementation. Retatrutide produces overlapping magnitude with a reversible, non-surgical, self-administered weekly injection.

The other framing-shift comes from the BMI categorical outcome reported in the same press release: 65.3% of 12 mg patients reached BMI below 30, meaning they no longer met the WHO obesity threshold at the end of the trial [1]. That is the largest reported rate of obesity reversal for any pharmacological therapy.

Waist circumference and responder rates

In its May 2026 press release, Lilly reported mean waist circumference reduction of 9.5 inches (about 24 cm) at the 12 mg dose on the efficacy estimand [1]. Waist circumference change is a clinically useful outcome separately from TBWL because it tracks visceral fat loss specifically, which is the adipose depot most strongly linked to cardiometabolic risk.

Responder-rate categories are how trials communicate “your chance of hitting threshold X.” The TRIUMPH-1 12 mg rates from Lilly's press release (efficacy estimand) [1]:

  • 45.3% achieved at least 30% body-weight reduction (the bariatric-surgery-overlap zone)
  • 65.3% achieved a BMI below 30 (no longer clinically obese)

For comparison, SURMOUNT-1 tirzepatide 15 mg reported about 57% of patients hit at least 20% TBWL [5]. STEP-1 semaglutide 2.4 mg reported about 32% hit at least 20% [6]. Retatrutide 12 mg shifts the entire distribution rightward — the 30% threshold becomes achievable for nearly half the trial population. Our retatrutide vs tirzepatide mechanism comparison walks through why the two drugs differ.

How TRIUMPH-1 compares to Wegovy, Zepbound, and Foundayo

The most useful “before and after” mental model is a side-by-side comparison of approved-drug magnitudes, because most patients have either tried or considered Wegovy, Zepbound, or Foundayo before they encounter retatrutide:

DrugMechanismHighest reported mean TBWLTrial / endpoint
Wegovy (semaglutide 2.4 mg)GLP-1-14.9%STEP-1, 68 wk[6]
Zepbound (tirzepatide 15 mg)GLP-1 + GIP-20.9%SURMOUNT-1, 72 wk[5]
Foundayo (orforglipron 36 mg)Oral small-molecule GLP-1about -11.2%ATTAIN-1, 72 wk[7]
Retatrutide 12 mgGLP-1 + GIP + glucagon-25.0% (80 wk); -30.3% (104 wk ext., Lilly press release)TRIUMPH-1[13][1]

Retatrutide's published 25.0% at 80 weeks is roughly 1.7x larger than Wegovy, 1.2x larger than Zepbound (about 4.1 percentage points), and 2.2x larger than Foundayo at each drug's respective pivotal endpoint. These are cross-trial comparisons, not head-to-head results. For deeper trial-by-trial analysis, see our Wegovy vs Ozempic evidence review and our tirzepatide vs semaglutide head-to-head.

Real-world expectations vs trial mean

Pivotal-trial populations are not typical real-world patient populations. Trial participants get free drug, free clinic visits, monthly lifestyle counseling, structured titration support, and they enrolled because they were motivated enough to commit to 80-104 weeks of weekly injections plus scheduled study visits. Real-world patients miss doses, pause for vacations or supply gaps, manage side effects without on-call clinic support, and often discontinue prematurely.

Published real-world data for the GLP-1 class come in well below pivotal-trial means. In a Cleveland Clinic electronic-health-record cohort of 3,389 adults treated with injectable semaglutide or liraglutide, 1-year mean total body-weight loss among patients treated for obesity (semaglutide or liraglutide) was 5.9% — versus 14.9% at 68 weeks in STEP 1 [6], or about 40% of the pivotal mean (Gasoyan 2024 JAMA Netw Open, PMID 39269703) [11]. Among patients with persistent medication coverage (cumulative gap under 90 days at 1 year), the mean was 5.5%; among those with under 90 days of coverage, only 1.8% [11]. Applied to retatrutide 12 mg's published -25.0%, that evidence-based real-world expectation is in the roughly 8-13% TBWL range at 80 weeks for the average patient, with the most adherent subset approaching 13-15%. Patients who discontinue early regain much of their loss: the STEP 1 trial extension (Wilding 2022, PMID 35441470) reported that one year after stopping weekly semaglutide 2.4 mg, participants regained roughly two-thirds of their prior weight loss, with net loss falling from 17.3% on treatment to 5.6% at week 120 [9]. SURMOUNT-4 (tirzepatide withdrawal) showed a more modest regain pattern. There is no reason to expect retatrutide will behave differently in this regard, and patients should plan on long-term — not time-limited — therapy.

Why we don't post patient photos

Three reasons we anchor this article on numeric magnitude rather than visual before-and-after imagery:

  1. Photos don't generalize. Any specific patient's transformation reflects their starting BMI, body composition, dose tolerated, adherence, baseline diet, baseline activity level, and underlying medical comorbidities. The trial mean is statistical, not aesthetic.
  2. Stock-photo before-and-afters are usually fake. The same models appear in promotions for unrelated weight-loss products. Using them implies patient-specific results we cannot verify.
  3. Our editorial standard. For your-money-or-your-life health content, the responsible framing is verified primary-source magnitude with appropriate caveats, not visual marketing that bypasses the citation chain.

If you want to see what a 25% or 30% body-weight loss looks like on your own frame, the most honest tool is a body-weight calculation, not a stranger's photo: multiply your current weight by 0.75 (for the published -25.0%) or by 0.697 (for the press-release extension figure of -30.3%) and compare to the BMI categorical line for your height.

When will retatrutide be available?

As of October 2026: TRIUMPH-1 is published in the New England Journal of Medicine (September 2026)[13], retatrutide is still not FDA-approved, and Lilly has not announced a US brand name. On July 23, 2026, Lilly announced positive topline results from two more pivotal Phase 3 trials — TRIUMPH-2 (NCT05929079, n=1,152, adults with type 2 diabetes and obesity/overweight) and TRIUMPH-3 (NCT05882045, 1,949 randomized per Lilly, adults with severe obesity and established cardiovascular disease) — and stated it plans to submit a Biologics License Application (BLA) to the FDA in Q1 2027[12]. Per Lilly, the filing will follow completion of its chemistry, manufacturing, and controls (CMC) data package. Using the standard FDA review timelines — 6-10 months for priority review, 10-12 months for standard review — a Q1 2027 filing pushes likely US availability to roughly late 2027 at the earliest, more realistically 2028, later than this article's earlier estimate. TRIUMPH-2 reported 80-week body-weight reductions of −20.8% (12 mg) and −19.1% (9 mg) vs −4.0% placebo, with A1C reductions up to −1.6%; TRIUMPH-3 reported −22.6% (12 mg) and −21.6% (9 mg) vs −3.2% placebo at 80 weeks[12] — both somewhat lower than TRIUMPH-1's general-obesity-population magnitude, consistent with the pattern that comorbid populations (diabetes, established cardiovascular disease) tend to show smaller GLP-1-class weight-loss effect sizes. Those July figures are Lilly's press-release (efficacy-estimand) numbers, so they should be compared with TRIUMPH-1's press-release -28.3% rather than its published -25.0%. TRIUMPH-2 has since been published in The Lancet (September 2026).

For tracking the FDA-filing and label-content milestones, plus the broader pipeline (CagriSema, MariTide, survodutide, Ecnoglutide), see our GLP-1 trial results quarterly and the access-timeline companion retatrutide approval and access timeline. For the foundational triple-agonist mechanism deep-dive and the Phase 2 (Jastreboff 2023 NEJM) data, see our retatrutide triple agonist evidence review. For the verified safety signal profile from the TRIUMPH program, see the retatrutide side-effects comprehensive evidence article. For the broader lipid-and-metabolite secondary profile published by Pearson et al. in JCEM May 2026, see citation [4] below.

Side-by-side magnitude chart

Magnitude comparison

Mean total body-weight reduction at trial endpoint — retatrutide TRIUMPH-1 dose-response (4/9/12 mg) compared with FDA-approved Wegovy (semaglutide), Zepbound (tirzepatide), and Foundayo (oral orforglipron). 80-week retatrutide values are the published NEJM intention-to-treat results; the 104-week extension bar is Lilly’s press-release efficacy-estimand figure. Sources: TRIUMPH-1 (NEJM 2026; Lilly press release, May 2026); SURMOUNT-1; STEP-1; ATTAIN-1.[13][1][5][6][7]

  • Foundayo - orforglipron 36 mg (ATTAIN-1, 72 wk)11.2 % TBWL
  • Wegovy - semaglutide 2.4 mg (STEP-1, 68 wk)14.9 % TBWL
  • Retatrutide 4 mg (TRIUMPH-1, 80 wk)17.6 % TBWL
    starter dose exceeds Wegovy ceiling
  • Zepbound - tirzepatide 15 mg (SURMOUNT-1, 72 wk)20.9 % TBWL
  • Retatrutide 9 mg (TRIUMPH-1, 80 wk)23.7 % TBWL
  • Retatrutide 12 mg (TRIUMPH-1, 80 wk)25.0 % TBWL
    primary endpoint at 80 wk (NEJM)
  • Retatrutide 12 mg (TRIUMPH-1 ext., BMI 35+, 104 wk)30.3 % TBWL
    Lilly press release, efficacy estimand
Mean total body-weight reduction at trial endpoint — retatrutide TRIUMPH-1 dose-response (4/9/12 mg) compared with FDA-approved Wegovy (semaglutide), Zepbound (tirzepatide), and Foundayo (oral orforglipron). 80-week retatrutide values are the published NEJM intention-to-treat results; the 104-week extension bar is Lilly’s press-release efficacy-estimand figure. Sources: TRIUMPH-1 (NEJM 2026; Lilly press release, May 2026); SURMOUNT-1; STEP-1; ATTAIN-1.

Further reading

Key terms, explained

New to GLP-1s? Tap any term for a quick, plain-English definition.

Frequently Asked Questions

In the published TRIUMPH-1 results (NEJM, September 2026; NCT05929066, n=2,339), mean total body-weight reduction at 80 weeks was -25.0% on the 12 mg dose, -23.7% on 9 mg, and -17.6% on the 4 mg starter dose, versus -3.9% on placebo, using the intention-to-treat (treatment-regimen) analysis. Lilly's May 2026 press release headlined -28.3% (about 70.3 lbs) for 12 mg, which is the efficacy-estimand figure for participants who stayed on treatment, and reported -30.3% (about 85.0 lbs) at 104 weeks in the BMI-35-or-higher extension cohort on the same basis.
Retatrutide 12 mg at 80 weeks (-25.0% TBWL in the published TRIUMPH-1 analysis) is roughly 1.7 times larger than Wegovy 2.4 mg at 68 weeks (-14.9% in STEP-1) and roughly 1.2 times larger than Zepbound 15 mg at 72 weeks (-20.9% in SURMOUNT-1), about 4.1 percentage points more. Even the retatrutide 4 mg starter dose (-17.6%) exceeds Wegovy 2.4 mg in STEP-1. Compared to oral orforglipron (Foundayo; -11.2% at the 36 mg trial dose in ATTAIN-1), retatrutide produces about 2.2 times the magnitude. These are cross-trial comparisons, not head-to-head trials.
According to Lilly's TRIUMPH-1 press release (efficacy estimand), 45.3% of patients on 12 mg achieved at least 30% body-weight reduction. The STAMPEDE 5-year RCT (Schauer 2017 NEJM) reported Roux-en-Y gastric bypass produced -23% mean body weight reduction and sleeve gastrectomy -19% in patients with T2D and mean baseline BMI ~37. So nearly half of retatrutide 12 mg responders fall in the same magnitude band as bariatric surgery, with the difference that the drug is reversible and non-surgical while surgery is permanent and carries surgical morbidity.
Three reasons: (1) photos don't generalize because results depend on starting BMI, body composition, dose tolerated, and adherence; (2) most before-and-after stock photos in weight-loss marketing recycle the same models across unrelated products; (3) our editorial standards require verified primary-source data with appropriate caveats, not visual marketing. We anchor expectations on TRIUMPH-1's mean and responder-rate data instead.
Probably not. Across the GLP-1 class, real-world weight loss runs well below pivotal-trial means because real-world patients miss doses, pause for supply or side-effect reasons, and discontinue earlier than trial participants; in a Cleveland Clinic cohort, patients treated for obesity with semaglutide or liraglutide averaged 5.9% at 1 year, about 40% of the STEP 1 result (Gasoyan 2024, PMID 39269703). Applied to retatrutide 12 mg's published -25.0%, that suggests roughly 8 to 13% TBWL for the average real-world patient, with the most adherent patients doing better.
In its May 2026 press release, Lilly reported a mean waist circumference reduction of 9.5 inches (about 24 cm) at the 12 mg dose at 80 weeks (efficacy estimand). Waist circumference is a useful complementary outcome to body weight because it specifically tracks visceral-fat reduction, which is the adipose depot most strongly linked to cardiometabolic risk.
As of October 2026, retatrutide is still not FDA-approved and Lilly has not announced a US brand name. TRIUMPH-1 was published in the New England Journal of Medicine in September 2026. In its July 23, 2026 topline release and its August 5, 2026 second-quarter earnings release, Lilly said it plans to submit a Biologics License Application (BLA) to the FDA in Q1 2027, after completing its chemistry, manufacturing, and controls data package. Standard FDA priority review is 6 to 10 months; standard review is 10 to 12 months. From a Q1 2027 filing, that puts likely US availability at roughly late 2027 at the earliest and more realistically 2028, later than earlier estimates anchored only to the TRIUMPH-1 readout.
Yes. TRIUMPH-1 was published in the New England Journal of Medicine in September 2026 (Jastreboff et al.), after topline results were released by Eli Lilly in May 2026 and presented at the 86th American Diabetes Association Scientific Sessions. The published intention-to-treat analysis reported -25.0% mean weight loss at 12 mg versus -3.9% on placebo at 80 weeks; the -28.3% figure in Lilly's press release is the efficacy estimand (participants who stayed on treatment). Two additional pivotal trials, TRIUMPH-2 (NCT05929079, type 2 diabetes + obesity) and TRIUMPH-3 (NCT05882045, severe obesity + cardiovascular disease), reported topline results on July 23, 2026; TRIUMPH-2 has since been published in The Lancet (September 2026). The earlier TRIUMPH program design paper (Giblin et al., Diabetes Obes Metab 2026, PMID 41090431) and the retatrutide lipid-and-metabolite secondary analysis (Pearson et al., JCEM 2026, PMID 42135195) are PubMed-indexed.
Weight loss with retatrutide, like the rest of the GLP-1 class, is progressive - it builds as the drug reaches steady state through the titration ladder, typically accelerating over the first three to six months and continuing toward the plateau seen at the trial endpoint. The Phase 2 retatrutide trial (the foundational study TRIUMPH-1 was designed to confirm) showed approximately 24 percent total body weight loss had accumulated by 48 weeks on the highest dose, suggesting that most of the final magnitude accrues steadily through the first year. For a concrete example, a 250-pound person reaching 20 pounds lost needs roughly an 8 percent reduction - a milestone most GLP-1 class responders can reach within the first 12 to 16 weeks on an escalating dose, though individual response, dose tolerated, and adherence all vary. Real-world weight loss typically runs 60 to 80 percent of pivotal-trial means, so expectations should be for steady, months-long progress rather than rapid early results.
TRIUMPH-1's headline results center on total body weight, BMI, and waist circumference - dedicated lean-mass or body-composition data were not part of the topline readout. Based on what the GLP-1 class broadly shows, a significant caloric deficit without resistance training and adequate protein reduces lean mass alongside fat, typically at a ratio of roughly one part muscle to three to four parts fat in sedentary weight loss. The standard approach during any GLP-1 class treatment is resistance training two to three times per week combined with a protein intake of roughly 1.2 to 1.6 grams per kilogram of body weight - there is no clinical reason retatrutide would differ from the class in this regard, and the magnitude of the deficit at 25 percent body weight loss makes that discipline more important, not less.

References

  1. 1.Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. (TRIUMPH-1 pivotal Phase 3 results presented at the American Diabetes Association 86th Scientific Sessions, May 2026.) PR Newswire (Eli Lilly Investor Release), May 2026. 2026. https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html
  2. 2.Eli Lilly and Company. A Study of Retatrutide (LY3437943) in Adult Participants With Obesity (TRIUMPH-1). ClinicalTrials.gov NCT05929066. 2026. https://clinicaltrials.gov/study/NCT05929066
  3. 3.Giblin K, Kaplan LM, Somers VK, Le Roux CW, Hunter DJ, Wu Q, Lalonde A, Ahmad N, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes, Obesity and Metabolism. 2026. PMID: 41090431.
  4. 4.Pearson MJ, Willency JA, Lin Y, Abadi A, Hartman ML, Coskun T, Ruotolo G, Duffin KL. Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes. J Clin Endocrinol Metab. 2026. PMID: 42135195.
  5. 5.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, et al.; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. PMID: 35658024.
  6. 6.Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, et al.; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. PMID: 33567185.
  7. 7.Wharton S, Aronne LJ, Stefanski A, Alfaris NF, Ciudin A, Yokote K, Halpern B, Shukla AP, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). N Engl J Med. 2025. PMID: 40960239.
  8. 8.American Diabetes Association. Eli Lilly and Company (presenting). TRIUMPH-1 Phase 3 Late-Breaking Symposium: Efficacy and Safety of Retatrutide in Adults with Obesity. 86th ADA Scientific Sessions, May 2026. 2026. https://professional.diabetes.org/scientific-sessions
  9. 9.Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Lingvay I, McGowan BM, et al.; STEP 1 Study Group. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022. PMID: 35441470.
  10. 10.Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Aminian A, Brethauer SA, et al.; STAMPEDE Investigators. Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes (STAMPEDE). N Engl J Med. 2017. PMID: 28199805.
  11. 11.Gasoyan H, Pfoh ER, Schulte R, Le P, Rothberg MB. One-Year Weight Reduction With Semaglutide or Liraglutide in Clinical Practice. JAMA Netw Open. 2024. PMID: 39269703.
  12. 12.Eli Lilly and Company. Lilly's Triple Agonist Retatrutide Successful in Two Additional Phase 3 Obesity Trials, Delivering Significant Improvements in Weight and A1C. TRIUMPH-2 (NCT05929079, n=1,152, type 2 diabetes + obesity/overweight) and TRIUMPH-3 (NCT05882045, 1,949 randomized per Lilly, severe obesity + established cardiovascular disease), 80-week topline results; Lilly stated plans to submit a Biologics License Application (BLA) to FDA in Q1 2027. PR Newswire (Eli Lilly Investor Release), July 23, 2026. 2026. https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-successful-in-two-additional-phase-3-obesity-trials-delivering-significant-improvements-in-weight-and-a1c-302832674.html
  13. 13.Jastreboff AM, Kaplan LM, Davies MJ, Wilding JPH, et al.; TRIUMPH-1 Investigators. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. 2026. PMID: 42814954.

Retatrutide TRIUMPH Phase 3: Latest Pipeline Update

In the TRIUMPH-1 phase 3 trial, Lilly's retatrutide produced up to 25.0% weight loss at 80 weeks, and 18.8% in people with type 2 diabetes in TRIUMPH-2. Lilly plans to file with the FDA in Q1 2027. Open safety questions and the access timeline are covered.

11 min read

Retatrutide Side Effects: Comprehensive Phase 3 Evidence Review

TRIUMPH-1 pivotal phase 3 retatrutide adverse-event review: GI rates, a dysesthesia signal (12.5% vs 0.9% placebo) also seen with high-dose semaglutide, 11.3% discontinuation, and head-to-head AE comparison with Wegovy, Zepbound, and Foundayo.

15 min read

Retatrutide vs Wegovy: cross-trial weight-loss + safety evidence (2026)

Retatrutide (investigational) -25.0% TBWL at 12 mg / 80 wk in TRIUMPH-1 vs Wegovy (FDA-approved 2021) -14.9% at 68 wk in STEP-1, about 1.7x on a cross-trial basis. No head-to-head RCT. Wegovy has SELECT (20% MACE reduction); retatrutide's outcomes trial is ongoing.

12 min read

Retatrutide vs Foundayo (orforglipron) — TRIUMPH-1 vs ATTAIN-1 cross-trial evidence

Retatrutide −25.0% TBWL at 12 mg / 80 wk (TRIUMPH-1, NEJM 2026) vs Foundayo (orforglipron) ~−11% at 17.2 mg / 72 wk (ATTAIN-1), roughly 2.2× on a cross-trial basis. Both are Eli Lilly molecules; Foundayo is FDA-approved (April 2026), retatrutide is investigational.

12 min read

Retatrutide Approval & Access Timeline: TRIUMPH Results, 2027 FDA Filing, No Compounding

Retatrutide is not FDA-approved. Lilly plans to file in the first quarter of 2027, so it will not be prescribable in 2026. TRIUMPH-1 showed up to 25.0% weight loss at 80 weeks, and it cannot legally be compounded under 503A or 503B.

12 min read

Retatrutide: What We Know About Lilly's Triple Agonist as TRIUMPH-4 Reads Out

Retatrutide is Lilly's investigational triple agonist of the GLP-1, GIP, and glucagon receptors. TRIUMPH-4 showed 28.7% mean weight loss at the highest dose in adults with obesity and knee osteoarthritis. Phase 3 also flagged a dysesthesia signal on the 12 mg dose.

13 min read

Where to get GLP-1 safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

8.3

Collective

The lowest flat medication price if you can absorb an annual membership fee

Read full review →

From $59/mo

+ required membership

Get started →
8.3

CoreAge Rx

Lowest-price compounded semaglutide and tirzepatide with one flat price at every dose

Read full review →

From $79/mo

starting price

Get started →
7.8

Embody

Low flat-rate compounded GLP-1 pricing at every dose

Read full review →

From $79/mo

sale price

Get started →

About this analysis

Weight Loss Rankings is an independent editorial publication. Our provider dataset is verified directly against each provider's website and updated continuously. Read our full methodology →